Is IBIO or TENX more profitable?

iBio's return on equity of -53.86% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Tenax Therapeutics N/A -56.32% -53.12%

Does the media refer more to IBIO or TENX?

In the previous week, Tenax Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 2 mentions for Tenax Therapeutics and 1 mentions for iBio. Tenax Therapeutics' average media sentiment score of 0.50 beat iBio's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBIO or FENC more profitable?

iBio has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Adherex Technologies -17.12% -43.87% -11.35%

Do analysts prefer SIGA or IBIO?

iBio has a consensus price target of $5.00, indicating a potential upside of 203.03%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Which has stronger earnings and valuation, SIGA or IBIO?

Siga Technologies has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $93.78M 3.29 $23.28M $0.27 15.93 iBio $400K 204.93 -$18.38M -$0.58 N/A

Is SIGA or IBIO more profitable?

Siga Technologies has a net margin of 21.58% compared to iBio's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Siga Technologies 21.58% 10.60% 8.94% iBio N/A -53.86% -46.48%

Which has preferable valuation and earnings, CLLS or IBIO?

iBio has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 3.66 -$67.59M -$0.67 N/A iBio $400K 204.93 -$18.38M -$0.58 N/A

Is CLLS or IBIO more profitable?

iBio has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. iBio's return on equity of -53.86% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% iBio N/A -53.86% -46.48%

Does the media prefer CLLS or IBIO?

In the previous week, Cellectis and Cellectis both had 1 articles in the media. Cellectis' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IBIO or DMAC more profitable?

iBio's return on equity of -53.86% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% DiaMedica Therapeutics N/A -77.15% -69.23%

Does the media favor IBIO or DMAC?

In the previous week, iBio and iBio both had 1 articles in the media. DiaMedica Therapeutics' average media sentiment score of 0.76 beat iBio's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DiaMedica Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iBio (IBIO) Competitors

$1.65 -0.09 (-5.17%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.68 +0.03 (+1.58%)

As of 06/23/2026 07:40 PM Eastern

Compare

IBIO vs. TENX, FENC, SIGA, CLLS, and DMAC

Should you buy iBio stock or one of its competitors? MarketBeat compares iBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iBio include Tenax Therapeutics (TENX), Adherex Technologies (FENC), Siga Technologies (SIGA), Cellectis (CLLS), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.

How does iBio compare to Tenax Therapeutics?

iBio (NASDAQ:IBIO) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

iBio has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	204.93	-$18.38M	-$0.58	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

In the previous week, Tenax Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 2 mentions for Tenax Therapeutics and 1 mentions for iBio. Tenax Therapeutics' average media sentiment score of 0.50 beat iBio's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio presently has a consensus price target of $5.00, suggesting a potential upside of 203.03%. Tenax Therapeutics has a consensus price target of $38.00, suggesting a potential upside of 178.59%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

iBio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

7.9% of iBio shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iBio's return on equity of -53.86% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Summary

iBio beats Tenax Therapeutics on 11 of the 15 factors compared between the two stocks.

How does iBio compare to Adherex Technologies?

iBio (NASDAQ:IBIO) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

7.9% of iBio shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

iBio has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Adherex Technologies	-17.12%	-43.87%	-11.35%

In the previous week, iBio had 1 more articles in the media than Adherex Technologies. MarketBeat recorded 1 mentions for iBio and 0 mentions for Adherex Technologies. iBio's average media sentiment score of 0.00 equaled Adherex Technologies'average media sentiment score.

Company	Overall Sentiment
iBio	Neutral
Adherex Technologies	Neutral

iBio currently has a consensus price target of $5.00, indicating a potential upside of 203.03%. Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 49.51%. Given iBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe iBio is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Adherex Technologies has higher revenue and earnings than iBio. Adherex Technologies is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	204.93	-$18.38M	-$0.58	N/A
Adherex Technologies	$44.64M	8.05	-$9.74M	-$0.29	N/A

Summary

iBio beats Adherex Technologies on 8 of the 15 factors compared between the two stocks.

How does iBio compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

In the previous week, iBio had 1 more articles in the media than Siga Technologies. MarketBeat recorded 1 mentions for iBio and 0 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score.

Company	Overall Sentiment
Siga Technologies	Neutral
iBio	Neutral

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Siga Technologies has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$93.78M	3.29	$23.28M	$0.27	15.93
iBio	$400K	204.93	-$18.38M	-$0.58	N/A

Siga Technologies has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

iBio has a consensus price target of $5.00, indicating a potential upside of 203.03%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Siga Technologies has a net margin of 21.58% compared to iBio's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
iBio	N/A	-53.86%	-46.48%

Summary

Siga Technologies and iBio tied by winning 8 of the 16 factors compared between the two stocks.

How does iBio compare to Cellectis?

Cellectis (NASDAQ:CLLS) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

In the previous week, Cellectis and Cellectis both had 1 articles in the media. Cellectis' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. iBio's return on equity of -53.86% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
iBio	N/A	-53.86%	-46.48%

iBio has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A
iBio	$400K	204.93	-$18.38M	-$0.58	N/A

Cellectis has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 141.38%. iBio has a consensus target price of $5.00, indicating a potential upside of 203.03%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

63.9% of Cellectis shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

iBio beats Cellectis on 9 of the 14 factors compared between the two stocks.

How does iBio compare to DiaMedica Therapeutics?

iBio (NASDAQ:IBIO) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, iBio and iBio both had 1 articles in the media. DiaMedica Therapeutics' average media sentiment score of 0.76 beat iBio's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio's return on equity of -53.86% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

iBio has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	204.93	-$18.38M	-$0.58	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

iBio currently has a consensus price target of $5.00, suggesting a potential upside of 203.03%. DiaMedica Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 96.39%. Given iBio's stronger consensus rating and higher probable upside, equities analysts plainly believe iBio is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

7.9% of iBio shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

iBio beats DiaMedica Therapeutics on 10 of the 14 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$86.44M	$930.38M	$4.35B	$12.39B
Dividend Yield	N/A	4.84%	10.93%	5.83%
P/E Ratio	-2.84	1.45	22.07	23.99
Price / Sales	204.93	119.61	163.26	107.77
Price / Cash	N/A	20.06	40.77	54.51
Price / Book	1.83	7.75	18.62	6.50
Net Income	-$18.38M	-$3.91M	$115.37M	$336.88M
7 Day Performance	3.12%	1.63%	-0.46%	-0.14%
1 Month Performance	-10.33%	2.02%	-1.84%	0.77%
1 Year Performance	N/A	52.11%	11.97%	28.49%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	2.3733 of 5 stars	$1.65 -5.2%	$5.00 +203.0%	N/A	$86.44M	$400K	N/A	100
TENX Tenax Therapeutics	2.9446 of 5 stars	$11.87 +4.8%	$39.67 +234.2%	+142.7%	$314.79M	N/A	N/A	9	Analyst Forecast Gap Down High Trading Volume
FENC Adherex Technologies	4.1251 of 5 stars	$8.98 +0.2%	$15.40 +71.5%	+27.6%	$313.29M	$51.00M	N/A	10	Gap Down
SIGA Siga Technologies	0.4437 of 5 stars	$4.31 +0.2%	N/A	-30.5%	$309.13M	$93.78M	15.96	40	Positive News
CLLS Cellectis	1.955 of 5 stars	$3.08 +1.0%	$7.00 +127.3%	+101.4%	$309.04M	$68.07M	N/A	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. TENX, FENC, SIGA, CLLS, and DMAC

How does iBio compare to Tenax Therapeutics?

Summary

How does iBio compare to Adherex Technologies?

Summary

How does iBio compare to Siga Technologies?

Summary

How does iBio compare to Cellectis?

Summary

How does iBio compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. TENX, FENC, SIGA, CLLS, and DMAC

How does iBio compare to Tenax Therapeutics?

Which has better valuation & earnings, IBIO or TENX?

Does the media refer more to IBIO or TENX?

Do analysts prefer IBIO or TENX?

Which has more risk & volatility, IBIO or TENX?

Do insiders & institutionals hold more shares of IBIO or TENX?

Is IBIO or TENX more profitable?

Summary

How does iBio compare to Adherex Technologies?

Do insiders & institutionals have more ownership in IBIO or FENC?

Which has more risk & volatility, IBIO or FENC?

Is IBIO or FENC more profitable?

Does the media prefer IBIO or FENC?

Do analysts rate IBIO or FENC?

Which has stronger earnings and valuation, IBIO or FENC?

Summary

How does iBio compare to Siga Technologies?

Does the media prefer SIGA or IBIO?

Do insiders & institutionals have more ownership in SIGA or IBIO?

Which has stronger earnings and valuation, SIGA or IBIO?

Which has more volatility & risk, SIGA or IBIO?

Do analysts prefer SIGA or IBIO?

Is SIGA or IBIO more profitable?

Summary

How does iBio compare to Cellectis?

Does the media prefer CLLS or IBIO?

Is CLLS or IBIO more profitable?

Which has preferable valuation and earnings, CLLS or IBIO?

Which has more volatility and risk, CLLS or IBIO?

Do analysts recommend CLLS or IBIO?

Do institutionals and insiders have more ownership in CLLS or IBIO?

Summary

How does iBio compare to DiaMedica Therapeutics?

Which has more risk & volatility, IBIO or DMAC?

Does the media favor IBIO or DMAC?

Is IBIO or DMAC more profitable?

Which has higher earnings and valuation, IBIO or DMAC?

Do analysts rate IBIO or DMAC?

Do institutionals and insiders believe in IBIO or DMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools